ASX - By Stock
|
OPT |
Re:
Analyst Upgrade
|
|
danny3
|
88 |
39K |
2 |
24/01/21 |
24/01/21 |
ASX - By Stock
|
88
|
39K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Ceasing to be a substantial holder
|
|
danny3
|
33 |
8.6K |
3 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
33
|
8.6K
|
3
|
|
ASX - By Stock
|
OPT |
Re:
News: OPT Opthea Priced IPO In U.S. Of 8.6 Million American Depositary Shares
|
|
danny3
|
10 |
5.9K |
0 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
10
|
5.9K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Announces Plans for Potential US listing and IPO
|
|
danny3
|
36 |
13K |
3 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
36
|
13K
|
3
|
|
ASX - By Stock
|
OPT |
Re:
Bell Potter includes OPT as pick for 2021
|
|
danny3
|
2 |
959 |
2 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
2
|
959
|
2
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
|
|
danny3
|
124 |
44K |
2 |
11/06/20 |
11/06/20 |
ASX - By Stock
|
124
|
44K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
explain the market cap
|
|
danny3
|
134 |
45K |
5 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
134
|
45K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
News: CUV UPDATE 1-U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment
|
|
danny3
|
121 |
59K |
0 |
20/04/20 |
20/04/20 |
ASX - By Stock
|
121
|
59K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Published BNC210 Phase 2b Data, Additional Information
|
|
danny3
|
19 |
5.4K |
0 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
19
|
5.4K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Published BNC210 Phase 2b Data, Additional Information
|
|
danny3
|
19 |
5.4K |
1 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
19
|
5.4K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Trading Halt
|
|
danny3
|
9 |
3.6K |
1 |
21/11/19 |
21/11/19 |
ASX - By Stock
|
9
|
3.6K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Chairman Address to the 2019 AGM
|
|
danny3
|
59 |
27K |
4 |
21/11/19 |
21/11/19 |
ASX - By Stock
|
59
|
27K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: IMM presents positive interim phase 2 TACTI-002 data at SITC
|
|
danny3
|
30 |
17K |
0 |
08/11/19 |
08/11/19 |
ASX - By Stock
|
30
|
17K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Konekt agrees to and supports increased offer
|
|
danny3
|
5 |
2.1K |
3 |
07/11/19 |
07/11/19 |
ASX - By Stock
|
5
|
2.1K
|
3
|
|
ASX - By Stock
|
KKT |
Re:
franking credits
|
|
danny3
|
8 |
2.2K |
0 |
03/11/19 |
03/11/19 |
ASX - By Stock
|
8
|
2.2K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
franking credits
|
|
danny3
|
8 |
2.2K |
1 |
30/10/19 |
30/10/19 |
ASX - By Stock
|
8
|
2.2K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
franking credits
|
|
danny3
|
8 |
2.2K |
2 |
28/10/19 |
28/10/19 |
ASX - By Stock
|
8
|
2.2K
|
2
|
|
ASX - By Stock
|
KKT |
franking credits
|
|
danny3
|
8 |
2.2K |
0 |
28/10/19 |
28/10/19 |
ASX - By Stock
|
8
|
2.2K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
Title moderated
|
|
danny3
|
3 |
2.6K |
1 |
18/10/19 |
18/10/19 |
ASX - By Stock
|
3
|
2.6K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
Is anyone else on here a Doctor or Biomedical researcher (etc)?
|
|
danny3
|
32 |
20K |
2 |
11/10/19 |
11/10/19 |
ASX - By Stock
|
32
|
20K
|
2
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Major Contract
|
|
danny3
|
17 |
6.5K |
4 |
08/10/19 |
08/10/19 |
ASX - By Stock
|
17
|
6.5K
|
4
|
|
ASX - By Stock
|
KKT |
Re:
Takeover offer
|
|
danny3
|
11 |
4.2K |
0 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
11
|
4.2K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
Takeover offer
|
|
danny3
|
11 |
4.2K |
0 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
11
|
4.2K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
price target
|
|
danny3
|
64 |
30K |
1 |
27/09/19 |
27/09/19 |
ASX - By Stock
|
64
|
30K
|
1
|
|
ASX - By Stock
|
OPT |
Re:
price target
|
|
danny3
|
64 |
30K |
5 |
17/09/19 |
17/09/19 |
ASX - By Stock
|
64
|
30K
|
5
|
|
ASX - By Stock
|
OPT |
Re:
Opthea Chart
|
|
danny3
|
238 |
116K |
2 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
238
|
116K
|
2
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
|
|
danny3
|
14 |
8.1K |
6 |
07/08/19 |
07/08/19 |
ASX - By Stock
|
14
|
8.1K
|
6
|
|
ASX - By Stock
|
KKT |
Re:
News: KKT Konekt Sees FY19 EBITDA Between $9.7 Mln And $9.9 Mln
|
|
danny3
|
6 |
4.3K |
1 |
23/07/19 |
23/07/19 |
ASX - By Stock
|
6
|
4.3K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Ceasing to be a substantial holder
|
|
danny3
|
2 |
1.4K |
0 |
13/06/19 |
13/06/19 |
ASX - By Stock
|
2
|
1.4K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Strategic Review Outcome and Program Updates
|
|
danny3
|
21 |
8.1K |
0 |
29/05/19 |
29/05/19 |
ASX - By Stock
|
21
|
8.1K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Results of the PTSD Trial and Exposure Analyses Presented
|
|
danny3
|
2 |
2.0K |
1 |
21/05/19 |
21/05/19 |
ASX - By Stock
|
2
|
2.0K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Company Secretary Appointment/Resignation
|
|
danny3
|
15 |
4.8K |
5 |
13/05/19 |
13/05/19 |
ASX - By Stock
|
15
|
4.8K
|
5
|
|
ASX - By Stock
|
BNO |
Re:
Technicals looking sick
|
|
danny3
|
34 |
11K |
1 |
31/03/19 |
31/03/19 |
ASX - By Stock
|
34
|
11K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
Ann: KKT Half Year Investor Presentation
|
|
danny3
|
13 |
5.0K |
1 |
20/02/19 |
20/02/19 |
ASX - By Stock
|
13
|
5.0K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
Capitulation time for Bionomics?
|
|
danny3
|
19 |
10K |
1 |
11/12/18 |
11/12/18 |
ASX - By Stock
|
19
|
10K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Leadership Changes and Strategic Review
|
|
danny3
|
15 |
6.6K |
2 |
10/11/18 |
10/11/18 |
ASX - By Stock
|
15
|
6.6K
|
2
|
|
ASX - By Stock
|
KKT |
Re:
News: KKT Konekt Reports FY Underlying Revenue Of $89.1 Million
|
|
danny3
|
9 |
2.9K |
1 |
03/11/18 |
03/11/18 |
ASX - By Stock
|
9
|
2.9K
|
1
|
|
ASX - By Stock
|
KKT |
Re:
lack of interest
|
|
danny3
|
9 |
3.3K |
0 |
31/10/18 |
31/10/18 |
ASX - By Stock
|
9
|
3.3K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Where is support for this stock once buying at 15c is filled?
|
|
danny3
|
18 |
6.4K |
2 |
30/10/18 |
30/10/18 |
ASX - By Stock
|
18
|
6.4K
|
2
|
|
ASX - By Stock
|
CUV |
Re:
Ann: NASDAQ Int Des Virtual Investor Conference Presentation
|
|
danny3
|
12 |
5.4K |
3 |
26/09/18 |
26/09/18 |
ASX - By Stock
|
12
|
5.4K
|
3
|
|
ASX - By Stock
|
PVE |
Re:
CREST account
|
|
danny3
|
3 |
1.5K |
0 |
18/06/18 |
18/06/18 |
ASX - By Stock
|
3
|
1.5K
|
0
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea Initiates OPT-302 Diabetic Macular Edema Trial
|
|
danny3
|
52 |
24K |
3 |
02/05/18 |
02/05/18 |
ASX - By Stock
|
52
|
24K
|
3
|
|
ASX - By Stock
|
OIL |
Re:
save optiscan website
|
|
danny3
|
80 |
27K |
0 |
17/04/18 |
17/04/18 |
ASX - By Stock
|
80
|
27K
|
0
|
|
ASX - By Stock
|
OIL |
Re:
Ann: Receipt of Shareholder requisition notice
|
|
danny3
|
74 |
23K |
0 |
16/03/18 |
16/03/18 |
ASX - By Stock
|
74
|
23K
|
0
|
|
ASX - By Stock
|
PVE |
Re:
Ann: Mutual Termination of Sale of PVO, PVE Retains Gas Fields
|
|
danny3
|
5 |
2.6K |
0 |
01/03/18 |
01/03/18 |
ASX - By Stock
|
5
|
2.6K
|
0
|
|
ASX - By Stock
|
PVE |
Re:
Ann: Mutual Termination of Sale of PVO, PVE Retains Gas Fields
|
|
danny3
|
5 |
2.6K |
0 |
01/03/18 |
01/03/18 |
ASX - By Stock
|
5
|
2.6K
|
0
|
|
ASX - By Stock
|
PVE |
Re:
Ann: Trading Halt
|
|
danny3
|
4 |
2.7K |
0 |
27/02/18 |
27/02/18 |
ASX - By Stock
|
4
|
2.7K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Konekt Investor Presentation
|
|
danny3
|
7 |
4.1K |
0 |
19/02/18 |
19/02/18 |
ASX - By Stock
|
7
|
4.1K
|
0
|
|
ASX - By Stock
|
KKT |
Re:
Ann: Konekt Investor Presentation
|
|
danny3
|
7 |
4.1K |
2 |
16/02/18 |
16/02/18 |
ASX - By Stock
|
7
|
4.1K
|
2
|
|
ASX - By Stock
|
OIL |
Re:
Ann: Market Update
|
|
danny3
|
6 |
3.0K |
5 |
22/12/17 |
22/12/17 |
ASX - By Stock
|
6
|
3.0K
|
5
|
|